Free Trial
NASDAQ:WGS

GeneDx (WGS) Stock Price, News & Analysis

GeneDx logo
$105.69 +8.80 (+9.08%)
Closing price 04:00 PM Eastern
Extended Trading
$106.50 +0.81 (+0.77%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GeneDx Stock (NASDAQ:WGS)

Key Stats

Today's Range
$101.06
$107.39
50-Day Range
$76.35
$112.76
52-Week Range
$10.18
$115.60
Volume
1.24 million shs
Average Volume
690,804 shs
Market Capitalization
$2.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.33
Consensus Rating
Moderate Buy

Company Overview

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

GeneDx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

WGS MarketRank™: 

GeneDx scored higher than 42% of companies evaluated by MarketBeat, and ranked 719th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GeneDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GeneDx has only been the subject of 1 research reports in the past 90 days.

  • Read more about GeneDx's stock forecast and price target.
  • Earnings Growth

    Earnings for GeneDx are expected to grow by 115.46% in the coming year, from $0.97 to $2.09 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GeneDx is -53.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GeneDx is -53.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    GeneDx has a P/B Ratio of 12.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about GeneDx's valuation and earnings.
  • Percentage of Shares Shorted

    11.28% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    GeneDx does not currently pay a dividend.

  • Dividend Growth

    GeneDx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.28% of the float of GeneDx has been sold short.
  • Short Interest Ratio / Days to Cover

    GeneDx has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in GeneDx has recently increased by 10.84%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    GeneDx has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for GeneDx this week, compared to 7 articles on an average week.
  • Search Interest

    12 people have searched for WGS on MarketBeat in the last 30 days. This is an increase of 9% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added GeneDx to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GeneDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,907,437.00 in company stock.

  • Percentage Held by Insiders

    27.30% of the stock of GeneDx is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    61.72% of the stock of GeneDx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GeneDx's insider trading history.
Receive WGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GeneDx and its competitors with MarketBeat's FREE daily newsletter.

WGS Stock News Headlines

[Action Required] Claim Your FREE IRS Loophole Guide
This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.
Craig-Hallum Sticks to Their Buy Rating for GeneDx Holdings (WGS)
GeneDx to acquire Fabric Genomics for $33M in cash at closing
See More Headlines

WGS Stock Analysis - Frequently Asked Questions

GeneDx's stock was trading at $76.86 at the beginning of 2025. Since then, WGS shares have increased by 37.5% and is now trading at $105.69.
View the best growth stocks for 2025 here
.

GeneDx Holdings Corp. (NASDAQ:WGS) announced its quarterly earnings results on Tuesday, February, 18th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.66. The company had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive trailing twelve-month return on equity of 3.33%.
Read the conference call transcript
.

GeneDx shares reverse split on the morning of Thursday, May 4th 2023. The 1-33 reverse split was announced on Thursday, May 4th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 4th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

GeneDx's top institutional investors include Assenagon Asset Management S.A. (0.38%), GAMMA Investing LLC (0.14%), Rhumbline Advisers (0.07%) and Harbor Capital Advisors Inc. (0.06%). Insiders that own company stock include Casdin Capital, Llc, School Of Medicine At Mo Icahn, Opko Health, Inc, Tactical Opportunit Blackstone, Kareem Saad, Richard C Pfenniger Jr, Richard C Pfenniger Jr, Jason Ryan, Daniel Emmett Clark, Isaac Ro, Eric Schadt, Karen Ann White, Kevin Feeley, Katherine Stueland, Shawn Assad, Richard Miao and Anthony Prentice.
View institutional ownership trends
.

Shares of WGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GeneDx investors own include Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

Last Earnings
2/18/2025
Today
4/23/2025
Next Earnings (Estimated)
4/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Health services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:WGS
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.33
High Stock Price Target
$118.00
Low Stock Price Target
$21.00
Potential Upside/Downside
-30.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
107.70
P/E Growth
N/A
Net Income
$-175,770,000.00
Pretax Margin
-31.52%

Debt

Sales & Book Value

Annual Sales
$305.45 million
Price / Cash Flow
N/A
Book Value
$8.78 per share
Price / Book
11.90

Miscellaneous

Free Float
19,971,000
Market Cap
$2.93 billion
Optionable
Optionable
Beta
1.93
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:WGS) was last updated on 4/23/2025 by MarketBeat.com Staff
From Our Partners